Search companies

Live

Tuesday, 17 November 2026 · 581 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Miro Sciences Pitches Stem Cell Therapy for Severe Crohn’s Disease

MSX: $0.052 +15.56% · MC: $16M

Miro Sciences’ investor presentation positions its StemSmart cell therapy for patients with severe Crohn’s disease who have failed existing treatments, and says the company is preparing for a planned Phase 2 trial in Australia and the United States. The presentation reports approximately $4 million in cash at the end of September and a market capitalisation of approximately $20 million as of November.

Source announcements: 2026-11-05 09:12 to 2026-11-05 09:12 Sydney time
Story updated 2026-11-05 09:14 Sydney time
SourcesIntroducing Miro Sciences Ltd - Presentation
Comments